My Instagram

MIT Sloan Healthcare Innovations Prize competition

News credit: MIT NEWS

A team from a Harvard Medical School affiliate saw its way clearly to victory at last night’s MIT Sloan Healthcare Innovation Prize competition, with contact lenses that deliver medications directly to the eye over days or weeks.

For its novel invention, Theraoptix took home the annual competition’s $25,000 grand prize, sponsored by health services firm Optum. In total, eight finalist teams pitched health care innovations to a panel of expert judges, from Optum and several local venture firms, and a capacity audience at the MIT Wong Auditorium in the Tang Center.

Winning a second-place prize of $2,000 was Strand Therapeutics, which is developing mRNA-based cancer-fighting drugs. A $500 audience-choice prize was awarded to Healthcare Hospitality Systems, developing directional sound systems for hospital rooms.

Made from FDA-approved materials, Theraoptix’s contact lenses deliver eye medication in a controlled, sustained release. Sandwiched between contact lens material is a drug-filled polymer film, formed into a tiny circular strip that doesn’t interfere with the wearer’s vision. The sandwiching structure causes the drugs to slowly seep from the film into the eye.

The lenses can be worn all day for up to two weeks to treat, say, glaucoma or to aid in healing after surgery. Eye drops are the traditional treatment method, but they can be ineffective, as the liquid drips out of the eye or patients may stop treatment. Moreover, the lenses can effectively deliver drugs to the back of the eye to treat macular degeneration, diabetic retinopathy, retinal vein occlusion, and other diseases that today require in-office injections.


“No eye drops, no injections — just one lens,” said team member Lokendra Bengani, a postdoc at Schepens Eye Research Institute of the Massachusetts Eye and Ear Infirmary, during the team’s winning pitch. Read more here:


Contact lenses that deliver drugs directly to the eye win health care prize








No comments